Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

HemAssist to enter phase III

June 28, 1996

SomatoKine covered under U.S. patent

June 28, 1996

Apolipoprotein B synthesis inhibitors reported

June 28, 1996

Phase III trial for Fortical approved in U.K.

June 28, 1996

C31G research results reported

June 21, 1996

Caverject cleared for marketing in Canada

June 21, 1996

Lilly's Humalog reaches first market

June 21, 1996

Teikoku Hormone reveals novel octadecapeptide

June 21, 1996

Lilly discloses insulin analogues

June 21, 1996

Ceredase approved in Japan

June 21, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...